Triple
T12385398
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Hal V. Barron |
E295849
|
entity |
| Predicate | employer |
P7
|
FINISHED |
| Object |
Calico Life Sciences
Calico Life Sciences is a biotechnology research company focused on understanding aging and age-related diseases, backed by Alphabet (Google’s parent company).
|
E979390
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Calico Life Sciences | Statement: [Hal V. Barron, employer, Calico Life Sciences]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Calico Life Sciences Context triple: [Hal V. Barron, employer, Calico Life Sciences]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Genocea Biosciences
Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Calico Life Sciences Triple: [Hal V. Barron, employer, Calico Life Sciences]
Generated description
Calico Life Sciences is a biotechnology research company focused on understanding aging and age-related diseases, backed by Alphabet (Google’s parent company).
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Calico Life Sciences Target entity description: Calico Life Sciences is a biotechnology research company focused on understanding aging and age-related diseases, backed by Alphabet (Google’s parent company).
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Genocea Biosciences
Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6ad9e653c8190b1473c860ee53dae |
completed | April 8, 2026, 7:33 p.m. |
| NER | Named-entity recognition | batch_69d93fbd489c819098233a111442762e |
completed | April 10, 2026, 6:21 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69f62ac939bc819081629b9eef20c4e7 |
completed | May 2, 2026, 4:48 p.m. |
| NEDg | Description generation | batch_69f62c7b28588190839c35c19856d16f |
completed | May 2, 2026, 4:55 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69f62e403a308190a2bba3fefc420932 |
completed | May 2, 2026, 5:02 p.m. |
Created at: April 8, 2026, 9:54 p.m.